文献速递脑血管病

大核心梗死(ASPECTS 0-2)患者血管内取栓:LASTE试验辅助分析

Endovascular Thrombectomy in Patients With Largest Baseline Infarcts (ASPECTS 0-2): An Ancillary Analysis of the LASTE Trial.
PubMed 文献 · Stroke · 2026-04-14

该研究为LASTE随机试验的事后分析,纳入181例ASPECTS 0-2的前循环大血管闭塞患者。结果显示血管内取栓(EVT)改善90天功能结局(广义优势比1.81),降低死亡率(38.4% vs 59.6%),并减少梗死体积增长,支持梗死体积本身不应排除EVT。

要点

  • ASPECTS 0-2患者EVT改善90天功能结局,广义优势比1.81(95%CI 1.32-2.47)。
  • EVT组死亡率38.4%低于单纯药物组59.6%,相对风险0.64(95%CI 0.47-0.89)。
  • EVT组24小时梗死体积增长较药物组平均减少70.3 mL(95%CI -94.2至-46.3)。

核心结论

  • 在ASPECTS 0-2的早期前循环大血管闭塞患者中,EVT改善功能结局并降低死亡率。
  • 梗死体积本身不应作为排除血管内治疗的标准。

研究设计与样本

  • LASTE试验的事后分析,该试验为多中心随机研究,纳入≤80岁、ASPECTS 0-5、前循环近端大血管闭塞且随机化在最后已知良好时间6.5小时内的患者。
  • 本次分析纳入ASPECTS 0-2亚组共181例,随机接受EVT联合药物治疗或单纯药物治疗。

主要发现

  • 181例患者中位年龄72岁,55.8%为女性,中位核心梗死体积156 mL(四分位距121-204 mL)。
  • 90天功能结局的广义优势比为1.81(95%CI 1.32-2.47),支持EVT组更优。
  • EVT组死亡率38.4%,药物组59.6%,相对风险0.64(95%CI 0.47-0.89)。
  • EVT组改良Rankin量表0-3分比例为31.4%,药物组为8.5%,相对风险3.69(95%CI 1.77-7.68)。
  • 24小时梗死体积增长的组间平均差为-70.3 mL(95%CI -94.2至-46.3),症状性颅内出血率分别为12.9%和4.5%(相对风险2.85,95%CI 0.94-8.60)。

关键数值与推荐

  • 主要结局为90天改良Rankin量表评分分布。
  • 次要结局包括死亡率、24小时梗死体积增长、症状性颅内出血发生率及180天改良Rankin量表评分。

临床怎么用

  • 对于年龄<80岁、发病6.5小时内、ASPECTS 0-2的前循环大血管闭塞患者,可考虑血管内取栓治疗。
  • 不应仅因基线梗死体积大而排除血管内取栓。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular thrombectomy (EVT) has demonstrated benefits in patients with ischemic stroke and large-vessel occlusions, but its efficacy and safety in patients with the largest baseline infarcts (Alberta Stroke Program Early Computed Tomography Score [ASPECTS] 0-2), remain controversial. This study aimed to evaluate the efficacy and safety of EVT in early presenting patients with ASPECTS 0 to 2 compared with medical care alone. METHODS: This post hoc analysis of the multicenter, randomized LASTE trial ([Large Stroke Therapy Evaluation]; patients ≤80 years, ASPECTS 0-5, proximal anterior circulation large-vessel occlusion, randomization within 6.5 hours of last known well) evaluated the subgroup with ASPECTS 0 to 2, representing those with large baseline infarcts without an upper size limit, randomized to receive EVT plus medical care or medical care alone. Primary outcomes included the distribution of the modified Rankin Scale score at 90 days. Secondary outcomes included mortality, infarct volume growth at 24 hours, the incidence of symptomatic intracranial hemorrhage and modified Rankin Scale score at 180 days. The LASTE trial was conducted and reported in accordance with the CONSORT guidelines (Consolidated Standards of Reporting Trials). RESULTS: Median age was 72 years and 55.8% were women. Among the 181 patients with ASPECTS 0 to 2 (median core volume 156 mL [25th-75th percentiles, 121-204 mL]), at 90 days after randomization, EVT improved functional outcomes (generalized odds ratio, 1.81 [95% CI, 1.32-2.47]) and reduced mortality (38.4% versus 59.6%; relative risk, 0.64 [95% CI, 0.47-0.89]), which translated predominantly into an increase in the proportion of modified Rankin Scale score of 0 to 3 in the EVT group (31.4% versus 8.5%; relative risk, 3.69 [95% CI, 1.77-7.68]). A significant reduction in infarct growth volume was observed in the EVT group compared with medical care (mean difference, -70.3 mL [95% CI, -94.2 to -46.3]). Rates of symptomatic intracranial hemorrhage were 12.9% versus 4.5%, respectively (relative risk, 2.85 [95% CI, 0.94-8.60]). CONCLUSIONS: EVT improves functional outcomes and reduces mortality in patients with ASPECTS 0 to 2. These findings support the concept that in patients aged <80 years presenting within early time window (6.5 hours) with unlimitedly large infarct (predominantly selected using magnetic resonance imaging), the infarct size in isolation should not be used to disqualify patients from endovascular treatment. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03811769.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Lapergue B, Arquizan C, Albucher JF, et al. Endovascular Thrombectomy in Patients With Largest Baseline Infarcts (ASPECTS 0-2): An Ancillary Analysis of the LASTE Trial. Stroke. 2026. PMID: 41979451. doi:10.1161/STROKEAHA.125.054161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。